×
About 10,443 results

ALLMedicine™ Osteosarcoma Center

Research & Reviews  3,938 results

Radiation-induced osteosarcoma in a patient with DICER1 syndrome.
https://doi.org/10.1002/pbc.29782
Pediatric Blood & Cancer; Tanimura K, Nakano Y et. al.

May 21st, 2022 - Radiation-induced osteosarcoma in a patient with DICER1 syndrome.|2022|Tanimura K,Nakano Y,Sato-Otsubo A,Yamasaki K,Fukushima H,|

Pediatric Osteosarcoma: Correlation of Imaging Findings with Histopathologic Features, ...
https://doi.org/10.1148/rg.210171
Radiographics : a Review Publication of the Radiological ... Nguyen JC, Baghdadi S et. al.

May 21st, 2022 - Osteosarcoma is the most common primary bone sarcoma in children. Imaging plays a pivotal role in diagnostic workup, surgical planning, and follow-up monitoring for possible disease relapse. Survival depends on multiple factors, including presence...

Intralesional margin after excision of a high-grade osteosarcoma: Is it a catastrophe?
https://doi.org/10.1002/jso.26926
Journal of Surgical Oncology; Tsagkozis P, Gaston CL et. al.

May 20th, 2022 - Treatment of high-grade osteosarcoma (OS) relies on a combination of systemic chemotherapy and radical surgical excision of the tumor. Little is known on what happens in case of an irrefutably inadequate (intralesional) margin. We aimed to describ...

KDM3A-mediated SP1 activates PFKFB4 transcription to promote aerobic glycolysis in oste...
https://doi.org/10.1186/s12885-022-09636-8 10.1016/j.canlet.2016.11.019 10.1093/annonc/mdq276 10.3390/cells9040976 10.1200/JCO.2014.59.4895 10.1200/JCO.2008.16.2305 10.3389/fonc.2020.00013 10.3390/ijms22168869 10.1016/j.canlet.2014.04.001 10.1146/annurev-cellbio-092910-154237 10.1016/j.tibs.2015.12.001 10.1186/s12935-020-01494-3 10.3892/or.2020.7611 10.1038/nrg3173 10.1371/journal.pone.0060549 10.3390/cancers12051098 10.1038/onc.2017.44 10.1016/j.aanat.2010.07.010 10.1111/febs.13148 10.3748/wjg.v20.i38.13705 10.1016/j.cell.2006.03.027 10.1002/pro.3715 10.1093/nar/gkaa970 10.1093/nar/28.1.27 10.2147/OTT.S274744 10.1126/science.1223730 10.1038/onc.2015.309 10.18632/oncotarget.15681 10.3390/cancers11081122 10.1186/s12967-021-02881-8 10.18632/oncotarget.12310 10.1074/jbc.RA118.001730 10.1038/onc.2013.541 10.1080/14728222.2017.1391791 10.1002/ijc.26501 10.1177/15353702211023473 10.1016/j.ijbiomac.2018.12.105 10.1016/j.cbi.2021.109759 10.1038/onc.2017.13 10.1016/j.molcel.2019.09.019 10.1016/j.molcel.2016.02.011 10.1053/j.gastro.2019.08.018 10.1016/j.pharmthera.2015.05.008 10.1016/j.bbrc.2020.01.063 10.2174/157340611796799203 10.1139/bcb-2019-0111 10.1007/s10637-016-0417-9 10.1016/j.omto.2020.06.012 10.1093/carcin/bgs196 10.1038/s41586-018-0018-1 10.1146/annurev.bi.64.070195.004055 10.7150/thno.28721 10.1111/dgd.12645 10.1016/j.urolonc.2010.08.018
BMC Cancer; Wang W, Wang B

May 20th, 2022 - Lysine-specific histone demethylase 3A (KDM3A) is a potent histone modifier that is frequently implicated in the progression of several malignancies. However, its role in aerobic glycolysis of osteosarcoma (OS) remains unclear. KDM3A expression in...

Melittin inhibits growth of human osteosarcoma 143B cells through induction of apoptosi...
https://doi.org/10.2174/1871520622666220509121627
Anti-cancer Agents in Medicinal Chemistry; Xie X, Li Y et. al.

May 18th, 2022 - Osteosarcoma is the commonly seen type of primary malignant bone tumors in children and adolescents. Partial patients with osteosarcoma cannot tolerate the side effects of chemotherapy drugs. Hence, it is urgent to find anti-osteosarcoma drugs wit...

see more →

Guidelines  4 results

Assessment of resection margins in bone sarcoma treated by neoadjuvant chemotherapy: Li...
https://doi.org/10.1016/j.otsr.2018.12.015
Orthopaedics & Traumatology, Surgery & Research : OTSR; Gomez-Brouchet A, Mascard E et. al.

Apr 10th, 2019 - Standardized reports are essential to meeting the bone sarcoma reference center certification requirements of the French National Cancer Institute (INCa). The usual classifications of the Musculoskeletal Tumor Society (MSTS), the American Joint Co...

ENCCA WP17-WP7 consensus paper on teenagers and young adults (TYA) with bone sarcomas.
https://doi.org/10.1093/annonc/mdu153
Annals of Oncology : Official Journal of the European Soc... Wilhelm M, Dirksen U et. al.

Jun 26th, 2014 - Teenagers and young adults (TYA) cancer contributes substantially to morbidity and mortality in a population with much to offer society. TYA place distinct challenges upon cancer care services, many reporting feeling marginalized and their needs n...

Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
https://doi.org/10.1093/annonc/mdn102
Annals of Oncology : Official Journal of the European Soc... Bielack S, Carrle D et. al.

May 9th, 2008 - Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.|2008|Bielack S,Carrle D,Jost L, ,|diagnosis,epidemiology,pathology,therapy,therapy,diagnosis,epidemiology,pathology,therapy,

Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the ...
https://doi.org/10.1002/pbc.21596
Pediatric Blood & Cancer; Meyer JS, Nadel HR et. al.

May 6th, 2008 - The Children's Oncology Group (COG) is a multi-institutional cooperative group dedicated to childhood cancer research that has helped to increase the survival of children with cancer through clinical trials. These clinical trials include a standar...

see more →

Drugs  40 results see all →

Clinicaltrials.gov  71 results

Losartan + Sunitinib in Treatment of Osteosarcoma
https://clinicaltrials.gov/ct2/show/NCT03900793

May 13th, 2022 - This study is a Phase 1/1b clinical trial that aims to determine the Maximally Tolerated Dose of Losartan and Sunitinib Combination Therapy. Patients will first be accrued to the Dose Escalation phase of the study, using a 3+3 design. Medication d...

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
https://clinicaltrials.gov/ct2/show/NCT03449901

May 11th, 2022 - The investigators have recently demonstrated that argininosuccinate synthase 1 (ASS1) expression is silenced in 88% of all sarcomas (n=708), and that this loss is associated with a decreased overall survival. Using the extracellular arginine deple...

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04870944

May 10th, 2022 - PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of FACT complex-targeting curaxin CBL0137 (CBL0137) administered via infusion on Day 1 and Day 8 of a 21-day cycle to children with recurren...

Nasturtium (Tropaeolum Majus L) Intake and Biochemical Parameters in Pre-diabetic Subjects in Bogota Colombia
https://clinicaltrials.gov/ct2/show/NCT05346978

Apr 26th, 2022 - Epidemiological and animal studies have shown that consumption of fruits and vegetables decreases the risk of chronic diseases. Especially in T2D, the primary prevention is considered as a public health priority. Some studies show an inverse assoc...

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
https://clinicaltrials.gov/ct2/show/NCT04040205

Apr 5th, 2022 - Population to be studied: Since abemaciclib is already being studied in dedifferentiated liposarcoma patients, patients with this sarcoma subtype will not be enrolled in the current study. This exploratory study will enroll patients with all other...

see more →

News  112 results

FDA Accepts NDA Resubmission for Pedmark in Prevention of Platinum-Induced Ototoxicity in Solid Tumors
https://www.onclive.com/view/fda-accepts-nda-resubmission-for-pedmark-in-prevention-of-platinum-induced-ototoxicity-in-solid-tumors

Apr 28th, 2022 - The FDA has accepted for filing the new drug application (NDA) resubmission for a unique formulation of sodium thiosulfate (Pedmark) for the prevention of platinum-induced ototoxicity in patients between the ages of 1 month and 18 years who have l...

NDA Resubmitted to FDA for Pedmark in Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors
https://www.onclive.com/view/nda-resubmitted-to-fda-for-pedmark-in-prevention-of-cisplatin-induced-ototoxicity-in-solid-tumors

Apr 28th, 2022 - The new drug application seeking the approval of a unique formulation of sodium thiosulfate (Pedmark) for the prevention of ototoxicity induced by cisplatin chemotherapy in patients aged 1 month to less than 18 years of age with localized, nonmeta...

Genes Related to Osteosarcoma Survival Identified
https://www.medscape.com/viewarticle/960703

Oct 12th, 2021 - Investigators in China have identified 14 immune-related genes associated with survival in osteosarcoma. When they combined them into a risk score and added one additional factor – metastases at diagnosis – the model was an "excellent" predictor o...

Key Advances in Sarcoma Lead to More Personalized Medicine Efforts
https://www.onclive.com/view/key-advances-in-sarcoma-lead-to-more-personalized-medicine-efforts

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Soft tissue sarcoma treatments have significantly advanced within the past year with new available agents, others in the pipeline, and the continued search for biomarkers to make treatment more personalized for patients...

Intriguing Research Brings Hope to Orthopedic Oncology
https://www.onclive.com/view/intriguing-research-brings-hope-to-orthopedic-oncology

Oct 6th, 2021 - R. Lor Randall, MD, FACS The orthopedic oncology community has not seen many treatment advances due to the rarity of bone cancers, but emerging research could serve as a turning point for the specialized paradigm, explained R. Lor Randall, MD, FA...

see more →

Patient Education  12 results see all →